Zacks Investment Research upgraded shares of Akcea Therapeutics (NASDAQ:AKCA) from a sell rating to a hold rating in a research note issued to investors on Monday.

According to Zacks, “Akcea Therapeutics, Inc. is a biopharmaceutical company. It focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The Company’s drug pipeline consists of volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx which are in clinical stage. Akcea Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

How to Become a New Pot Stock Millionaire

Other equities research analysts have also recently issued research reports about the stock. BidaskClub raised shares of Akcea Therapeutics from a hold rating to a buy rating in a research report on Tuesday, March 6th. Stifel Nicolaus boosted their target price on shares of Akcea Therapeutics from $20.00 to $30.00 and gave the company a buy rating in a research report on Friday, March 16th. Cowen cut shares of Akcea Therapeutics from an outperform rating to a market perform rating in a research report on Tuesday, February 27th. Wells Fargo cut shares of Akcea Therapeutics from an outperform rating to a market perform rating and set a $27.00 target price for the company. in a research report on Tuesday, February 27th. Finally, BMO Capital Markets boosted their target price on shares of Akcea Therapeutics from $25.00 to $30.00 and gave the company an outperform rating in a research report on Tuesday, February 27th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Akcea Therapeutics has a consensus rating of Buy and an average price target of $24.75.

Shares of Akcea Therapeutics stock opened at $32.30 on Monday. Akcea Therapeutics has a 52-week low of $8.10 and a 52-week high of $33.99.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Legal & General Group Plc bought a new stake in Akcea Therapeutics during the third quarter worth about $111,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Akcea Therapeutics during the third quarter worth about $180,000. SG Americas Securities LLC bought a new stake in Akcea Therapeutics during the fourth quarter worth about $121,000. Nationwide Fund Advisors bought a new stake in Akcea Therapeutics during the third quarter worth about $209,000. Finally, Wells Fargo & Company MN bought a new stake in Akcea Therapeutics during the third quarter worth about $222,000. 29.14% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Akcea Therapeutics (AKCA) Upgraded at Zacks Investment Research” was first posted by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.watchlistnews.com/akcea-therapeutics-akca-upgraded-at-zacks-investment-research/1955495.html.

About Akcea Therapeutics

Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).

Get a free copy of the Zacks research report on Akcea Therapeutics (AKCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.